A Phase 4 interventional study of CREXONT ER in Parkinson Disease, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by The Cleveland Clinic · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Parkinson Disease by The Cleveland Clinic — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · The Cleveland Clinic.
Among the 15 studies in Parkinson Disease by The Cleveland Clinic, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 4, and was the 11th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 15 studies in Parkinson Disease by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+
The Cleveland Clinic
Ages 18+
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 22 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 38 across the 14 interventional studies, 15 across the 1 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
3 of the studies in Parkinson Disease by The Cleveland Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07110376The Cleveland ClinicDeep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease | 2026-12-31 |
| NCT07138560The Cleveland ClinicBOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease | 2027-02-15 |
| NCT07748962The Cleveland ClinicDecoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease | 2027-03-18 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Parkinson Disease by The Cleveland Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.
This research is being done because a new, longer-duration formulation of levodopa named IPX203 (brand name: Crexont®) has been recently approved by the FDA. The pivotal study on this drug demonstrated that IPX203 significantly increased the daily good on-time compared to immediate release carbidopa-levodopa (IR CD-LD), where good on-time is the time when the Parkinson's symptoms are improved without troublesome dyskinesias. In that study, the participants were taking IPX203 a mean of 3 times per day which still left a mean of 4.18 hours of off-time per day (when symptoms returned). These data were based on diaries filled out by the participants.
The aim of the study is to expand the current knowledge on IPX203, analyzing the changes in good on-time after careful and tailored adjustments, as in the real-world setting. This will be done with the assistance of a wearable device to obtain objective data. Additional variables such as changes in the tremor scores, conversion from other drugs such as Rytary and COMT inhibitors, and the difference between starting and final IPX203 doses will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention arm will be patients converting to shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods and other parameters using the KinesiaU device, could reveal additional benefits of Crexont (IPX203) treatment.
Drug: CREXONT ER
exploring shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods
Also known as: IPX203
Primary Endpoint
Mean change in the average duration of good on-time from baseline to end of study
Time frame: 8 weeks
Secondary Endpoint
Mean change in the average 'slowness' scores as measured by KinesiaU
Time frame: 8 weeks
Secondary Endpoint
Mean change in time spent with tremor as measured by KinesiaU
Time frame: 8 weeks
Secondary Endpoint
Mean change in the average tremor scores as measured by KinesiaU
Time frame: 8 weeks
Secondary Endpoint
Mean change in time spent with dyskinesia as measured by KinesiaU
Time frame: 8 weeks
Secondary Endpoint
Mean change in the continuous on time as measured by KinesiaU
Time frame: 8 weeks
Exploratory Endpoints
Mean difference between KinesiaU and PD diary measurements of change in good on-time from baseline to end of study
Time frame: 8 weeks
Exploratory Endpoint
Difference in the Patient Global Impression of Change from baseline to end of study.
Time frame: 8 weeks
Exploratory Endpoint
Difference between Non-Motor Fluctuation Assessment Questionnaire from baseline to end of study.
Time frame: 8 weeks
Exploratory Endpoint
The average time (in weeks) taken to reach the final dose.
Time frame: 8 weeks
Exploratory Endpoint
The average number of adjustments needed to reach the final dose.
Time frame: 8 weeks
Plan to share: No
Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.
Of 42 non-industry phase 4 interventional studies under Parkinson Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 75. This study's planned 18 months is below that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 19 and three quarters within 65.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Dec 2026 → Feb 2027 and completion May 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IPX203